Atrial-selective sodium channel block for the treatment of atrial fibrillation

Expert Opin Emerg Drugs. 2009 Jun;14(2):233-49. doi: 10.1517/14728210902997939.


The pharmacological approach to therapy of atrial fibrillation (AF) is often associated with adverse effects resulting in the development of ventricular arrhythmias. As a consequence, much of the focus in recent years has been on development of atrial-selective agents. Atrial-selective sodium channel blockers have recently been shown to exist and be useful in the management of AF. This review summarizes the available data relative to current therapies, focusing on our understanding of the actions of atrial selective sodium channel blockers in suppressing and preventing the induction of AF and electrophysiological properties that confer atrial-selectivity to these antifibrillatory drugs.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Anti-Arrhythmia Agents / pharmacology*
  • Anti-Arrhythmia Agents / therapeutic use*
  • Atrial Fibrillation / drug therapy*
  • Atrial Fibrillation / physiopathology
  • Drug Delivery Systems
  • Heart Atria / drug effects*
  • Heart Atria / physiopathology
  • Humans
  • Molecular Structure
  • Sodium Channel Blockers / pharmacology*
  • Sodium Channel Blockers / therapeutic use*


  • Anti-Arrhythmia Agents
  • Sodium Channel Blockers